Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
CanSino Biologics, Inc. Class H ( (HK:6185) ) has issued an update.
CanSino Biologics Inc. has announced its audited consolidated annual results for the year ending December 31, 2024. The results, which comply with the Hong Kong Stock Exchange’s listing requirements, have been reviewed and confirmed by the company’s board and audit committee. The annual report will be available to shareholders and on relevant websites, reflecting the company’s commitment to transparency and regulatory compliance.
More about CanSino Biologics, Inc. Class H
CanSino Biologics Inc. is a biotechnology company based in China, primarily focused on the development and production of innovative vaccines. It operates within the biopharmaceutical industry, targeting global markets with its vaccine products.
YTD Price Performance: 9.05%
Average Trading Volume: 1,343,043
Technical Sentiment Signal: Sell
Current Market Cap: HK$10.4B
For detailed information about 6185 stock, go to TipRanks’ Stock Analysis page.